|
WO2018097308A1
(ja)
|
2016-11-28 |
2018-05-31 |
中外製薬株式会社 |
リガンド結合活性が調整可能なリガンド結合分子
|
|
TWI797097B
(zh)
|
2016-11-28 |
2023-04-01 |
日商中外製藥股份有限公司 |
包含抗原結合域與運送部分的多胜肽
|
|
US11629340B2
(en)
|
2017-03-03 |
2023-04-18 |
Obsidian Therapeutics, Inc. |
DHFR tunable protein regulation
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
DK3661954T3
(da)
|
2017-08-03 |
2022-04-19 |
Amgen Inc |
Interleukin-21-muteiner og fremgangsmåder til behandling
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
CN111630062A
(zh)
|
2017-11-28 |
2020-09-04 |
中外制药株式会社 |
具有可调节的配体结合活性的配体结合分子
|
|
CN111836828B
(zh)
|
2017-11-28 |
2024-12-20 |
中外制药株式会社 |
包括抗原结合结构域和运送部分的多肽
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
USRE50550E1
(en)
|
2017-12-06 |
2025-08-26 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
TW201930344A
(zh)
|
2018-01-12 |
2019-08-01 |
美商安進公司 |
抗ｐｄ-１抗體及治療方法
|
|
CA3100005A1
(en)
|
2018-05-14 |
2019-11-21 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
AU2019271148B9
(en)
|
2018-05-14 |
2025-05-29 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
|
US11505618B2
(en)
*
|
2018-07-18 |
2022-11-22 |
Askgene Pharma Inc. |
Antibodies and methods for making and using the same
|
|
US12459980B2
(en)
|
2018-07-25 |
2025-11-04 |
AskGene Pharma, Inc. |
IL-21 prodrugs and methods of use thereof
|
|
WO2020057646A1
(zh)
|
2018-09-21 |
2020-03-26 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
EP3854805A4
(en)
*
|
2018-09-21 |
2022-08-24 |
Innovent Biologics (Suzhou) Co., Ltd. |
NOVEL INTERLEUKIN 2 AND ITS USE
|
|
CN120463822A
(zh)
|
2018-09-27 |
2025-08-12 |
西里欧发展公司 |
掩蔽型细胞因子多肽
|
|
KR20260039812A
(ko)
|
2019-02-06 |
2026-03-20 |
신톡스, 인크. |
Il-2 콘쥬게이트 및 이의 사용 방법
|
|
CN113710229B
(zh)
|
2019-02-25 |
2026-01-06 |
芝加哥大学 |
用与抗炎剂连接的ecm亲和肽治疗炎症性和自身免疫性病症的方法和组合物
|
|
KR20220023988A
(ko)
|
2019-05-14 |
2022-03-03 |
웨어울프 세라퓨틱스, 인크. |
분리 모이어티 및 이의 사용 방법
|
|
WO2020236875A1
(en)
|
2019-05-20 |
2020-11-26 |
Pandion Therapeutics, Inc. |
Madcam targeted immunotolerance
|
|
JP2022533254A
(ja)
*
|
2019-05-24 |
2022-07-21 |
プロヴィヴァ セラピューティクス （ホン コン） リミテッド |
Ｉｌ－２組成物およびその使用方法
|
|
KR20220020879A
(ko)
|
2019-06-12 |
2022-02-21 |
에스크진 파마, 아이엔씨. |
새로운 il-15 프로드럭 및 이를 사용하는 방법
|
|
EP4004026A4
(en)
*
|
2019-07-25 |
2023-11-15 |
Trutino Biosciences Inc. |
IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
|
|
WO2021024020A1
(en)
*
|
2019-08-06 |
2021-02-11 |
Astellas Pharma Inc. |
Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer
|
|
CA3148505A1
(en)
*
|
2019-08-12 |
2021-02-18 |
AskGene Pharma, Inc. |
Novel il-2 fusion molecules
|
|
MX2022002740A
(es)
|
2019-09-10 |
2022-03-25 |
Synthorx Inc |
Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
|
|
US20220356221A1
(en)
*
|
2019-09-28 |
2022-11-10 |
AskGene Pharma, Inc. |
Cytokine prodrugs and dual-prodrugs
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
MX2022007202A
(es)
*
|
2019-12-13 |
2022-10-07 |
Cugene Inc |
Fármacos bioactivables a base de citocinas y metodos de uso de los mismos.
|
|
BR112022012112A2
(pt)
|
2019-12-20 |
2022-09-06 |
Regeneron Pharma |
Agonistas de il2 e métodos de uso dos mesmos
|
|
KR20220118473A
(ko)
|
2019-12-23 |
2022-08-25 |
신톡스, 인크. |
N6-((2-아지도에톡시)카르보닐)라이신의 제조 방법
|
|
US11633488B2
(en)
|
2020-01-10 |
2023-04-25 |
Bright Peak Therapeutics Ag |
Modified IL-2 polypeptides and uses thereof
|
|
WO2021142471A1
(en)
*
|
2020-01-11 |
2021-07-15 |
AskGene Pharma, Inc. |
Novel masked cytokines and methods of use thereof
|
|
US20240043489A1
(en)
*
|
2020-01-15 |
2024-02-08 |
Trutino Biosciences Inc. |
Cytokine Prodrugs Comprising a Cleavable Linker
|
|
CN115943210A
(zh)
*
|
2020-01-20 |
2023-04-07 |
中外制药株式会社 |
配体结合融合蛋白
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
JP7773991B2
(ja)
*
|
2020-03-23 |
2025-11-20 |
ザイムワークス ビーシー インコーポレイテッド |
マスクされたｉｌ１２融合タンパク質及びその使用方法
|
|
IL296911A
(en)
*
|
2020-04-01 |
2022-12-01 |
Xilio Dev Inc |
Masked il-15 cytokines and their cleavage products
|
|
AU2021248919A1
(en)
*
|
2020-04-01 |
2022-10-13 |
Xilio Development, Inc. |
Masked IL-12 cytokines and their cleavage products
|
|
JP7735306B2
(ja)
*
|
2020-04-01 |
2025-09-08 |
エクシリオ デベロップメント， インコーポレイテッド |
マスクされたｉｌ－２サイトカイン及びその切断産物
|
|
AU2021254283B2
(en)
|
2020-04-10 |
2025-12-11 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
|
US11597753B2
(en)
*
|
2020-04-30 |
2023-03-07 |
Immune Targeting, Inc. |
Activatable IL2 composition and methods of use
|
|
WO2021231773A1
(en)
|
2020-05-13 |
2021-11-18 |
Good Therapeutics, Inc. |
Compositions of protein complexes and methods of use thereof
|
|
MX2023000734A
(es)
*
|
2020-07-14 |
2023-02-13 |
Pfizer |
Virus vaccinia recombinante.
|
|
US12421286B2
(en)
*
|
2020-09-04 |
2025-09-23 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
Il-2 mutant and application thereof
|
|
AU2021345852A1
(en)
*
|
2020-09-16 |
2023-05-25 |
Beone Medicines I Gmbh |
Interleukin 15 constructs and methods of use
|
|
JPWO2022059794A1
(https=)
*
|
2020-09-18 |
2022-03-24 |
|
|
|
TWI815194B
(zh)
*
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|
|
WO2022115865A2
(en)
*
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
EP4284819A1
(en)
*
|
2021-02-01 |
2023-12-06 |
Askgene Pharma, Inc. |
Chimeric molecules comprising an il-10 or tgf-beta agonist polypeptide
|
|
CN112553256B
(zh)
*
|
2021-02-20 |
2021-06-22 |
北京百普赛斯生物科技股份有限公司 |
Il-2受体复合物及其制备方法与应用
|
|
JP2024511387A
(ja)
|
2021-03-16 |
2024-03-13 |
シートムエックス セラピューティクス，インコーポレイテッド |
マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
|
BR112023021886A8
(pt)
*
|
2021-04-22 |
2024-01-09 |
Guangdong Fapon Biopharma Inc |
Polipeptídeo de fusão biespecífico multifuncional
|
|
TW202317623A
(zh)
|
2021-06-14 |
2023-05-01 |
美商再生元醫藥公司 |
基於il2之治療劑及其使用方法
|
|
US20240358849A1
(en)
*
|
2021-06-17 |
2024-10-31 |
Suzhou Fuse Biosciences Limited |
Immunoconjugate molecules and related methods and compositions thereof
|
|
US20230201365A1
(en)
*
|
2021-07-09 |
2023-06-29 |
Bright Peak Therapeutics Ag |
Modified cd20 antibodies and uses thereof
|
|
WO2023281485A1
(en)
|
2021-07-09 |
2023-01-12 |
Bright Peak Therapeutics Ag |
Modified il-2 polypeptides for treatment of inflammatory and autoimmune diseases
|
|
US20230181754A1
(en)
*
|
2021-07-09 |
2023-06-15 |
Bright Peak Therapeutics Ag |
Modified checkpoint inhibitors and uses thereof
|
|
US20240309061A1
(en)
*
|
2021-07-23 |
2024-09-19 |
Merck Sharp & Dohme Llc |
Il-2 muteins for treating cancer or infection
|
|
WO2023064791A1
(en)
*
|
2021-10-13 |
2023-04-20 |
Cytomx Therapeutics, Inc. |
Trimeric activatable cytokine constructs and related compositions and methods
|
|
EP4460512A4
(en)
*
|
2022-01-07 |
2026-01-14 |
Cure Genetics Co Ltd |
NEW INTERLEUKIN-2 POLYPEPTIDES
|
|
EP4473007A1
(en)
*
|
2022-01-31 |
2024-12-11 |
Aarhus Universitet |
A biopharmaceutical prodrug platform based on protein conformational change
|
|
CA3243623A1
(en)
*
|
2022-02-11 |
2025-01-20 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Immunoconjugated and its use
|
|
WO2023161853A1
(en)
|
2022-02-23 |
2023-08-31 |
Bright Peak Therapeutics Ag |
Activatable il-18 polypeptides
|
|
AU2023227283A1
(en)
*
|
2022-03-03 |
2024-09-19 |
Hainan Simcere Pharmaceutical Co., Ltd. |
Pharmaceutical composition of il2 mutant-antibody fc block fusion protein and use thereof
|
|
CN114853909A
(zh)
*
|
2022-05-13 |
2022-08-05 |
南京吉盛澳玛生物医药有限公司 |
新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
|
|
WO2023222886A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Depth Charge Ltd |
Antibody-cytokine fusion proteins
|
|
CN117917438A
(zh)
*
|
2022-10-21 |
2024-04-23 |
北京诺诚健华医药科技有限公司 |
抗体融合蛋白及其制备和应用
|
|
WO2024119193A2
(en)
*
|
2022-12-02 |
2024-06-06 |
AskGene Pharma, Inc. |
Mutant il-2 polypeptides and il-2 prodrugs
|
|
WO2024150175A1
(en)
|
2023-01-11 |
2024-07-18 |
Bright Peak Therapeutics Ag |
Conditionally activated proteins and methods of use
|
|
US20240417436A1
(en)
|
2023-01-11 |
2024-12-19 |
Bright Peak Therapeutics Ag |
Conditionally activated immunocytokines and methods of use
|
|
GB202301945D0
(en)
|
2023-02-10 |
2023-03-29 |
Mount Natalie |
Novel immunoconjugates
|
|
CN121219014A
(zh)
|
2023-04-17 |
2025-12-26 |
西纳福克斯股份有限公司 |
可切割的免疫细胞接合器
|
|
EP4450093A1
(en)
|
2023-04-17 |
2024-10-23 |
Synaffix B.V. |
Cleavable immune cell engagers
|
|
CN121487963A
(zh)
*
|
2023-06-22 |
2026-02-06 |
奥胡斯大学 |
多特异性蛋白质前药构建体
|
|
WO2025024658A1
(en)
*
|
2023-07-27 |
2025-01-30 |
Binacea Pharma, Inc. |
Mutant il-2 fusions with immune cell specific binding proteins and methods of use thereof
|
|
WO2025041101A1
(en)
|
2023-08-23 |
2025-02-27 |
Bright Peak Therapeutics Ag |
Activatable il-18 immunocytokines and uses thereof
|
|
CN120813378A
(zh)
*
|
2023-12-04 |
2025-10-17 |
奥美药业有限公司 |
包含掩蔽的il-2的嵌合蛋白
|
|
US20250179137A1
(en)
*
|
2023-12-05 |
2025-06-05 |
Regeneron Pharmaceuticals, Inc. |
Il18 receptor agonists and methods of use thereof
|
|
WO2025162454A1
(zh)
*
|
2024-02-02 |
2025-08-07 |
北京昌平实验室 |
双特异性抗体和细胞因子融合蛋白及其应用
|
|
WO2025165594A1
(en)
*
|
2024-02-02 |
2025-08-07 |
Staidson Biopharma Inc. |
Anti-pd-l1 and il-15 prodrug bifunctional protein and uses thereof
|
|
WO2025201242A1
(en)
*
|
2024-03-25 |
2025-10-02 |
Tavotek Biotherapeutics (Hong Kong) Limited |
Antibodies targeting fap and lrrc15 and fusion proteins targeting hyaluronan and uses thereof
|
|
CN119639683A
(zh)
*
|
2024-12-21 |
2025-03-18 |
浙江大学绍兴研究院 |
一种表达il-15靶向b7h3的嵌合抗原受体-t细胞及其应用
|